Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs enoxaparin for venous thromboembolism prophylaxis after elective total knee replacement surgery
2006-002161-39Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apixaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Primary composite efficacy endpoint (total DVT/PE/death) and Composite endpoint of proximal DVT/PE/death. Started Oct 2006; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2006-002161-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002161-39.